For instance, ripretinib, a switch control type II inhibitor of KIT, and avapritinib, a potent type I KIT/PDGFRα inhibitor, are both currently undergoing phase III trials in the third/fourth line-setting and may further improve the outcomes of patients with advanced GIST (NCT03353753, NCT03465722) [9,10]. Here, KIT is linked to gastrointestinal stromal tumor.